---
title: "Pharmaron Beijing Co., Ltd. Class H (17Q1) Gets a Buy from UBS"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/281286777.md"
description: "UBS has maintained a Buy rating on Pharmaron Beijing Co., Ltd. Class H, setting a price target of HK$32.90. The shares closed at HK$18.27 last Monday. The analyst consensus for the company is a Moderate Buy, with a price target consensus of €3.64."
datetime: "2026-04-01T01:45:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281286777.md)
  - [en](https://longbridge.com/en/news/281286777.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281286777.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/281286777.md) | [繁體中文](https://longbridge.com/zh-HK/news/281286777.md)


# Pharmaron Beijing Co., Ltd. Class H (17Q1) Gets a Buy from UBS

In a report released on March 30, from UBS maintained a Buy rating on Pharmaron Beijing Co., Ltd. Class H, with a price target of HK$32.90. The company’s shares closed last Monday at HK$18.27.

### End of Quarter Sale - 50% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Pharmaron Beijing Co., Ltd. Class H has an analyst consensus of Moderate Buy, with a price target consensus of €3.64.

### 相关股票

- [E Fund Hang Seng SCHK Innovative Drug ETF (159316.CN)](https://longbridge.com/zh-CN/quote/159316.CN.md)
- [PHARMARON (03759.HK)](https://longbridge.com/zh-CN/quote/03759.HK.md)
- [ChinaAMC CSI Biotechnology Theme ETF (516500.CN)](https://longbridge.com/zh-CN/quote/516500.CN.md)
- [E Fund CSI Biotechnology Theme ETF (159837.CN)](https://longbridge.com/zh-CN/quote/159837.CN.md)
- [Yinhua CSI Innovative Drugs Industry ETF (159992.CN)](https://longbridge.com/zh-CN/quote/159992.CN.md)
- [ChinaAMC Hang Seng Biotechnology Technology ETF(QDII) (159892.CN)](https://longbridge.com/zh-CN/quote/159892.CN.md)
- [ChinaAMC SSE STAR Biology and Medicine ETF (588130.CN)](https://longbridge.com/zh-CN/quote/588130.CN.md)
- [Bosera Hang Seng Health Care ETF(QDII) (513060.CN)](https://longbridge.com/zh-CN/quote/513060.CN.md)
- [Guotai CSI Bio-medicine ETF (512290.CN)](https://longbridge.com/zh-CN/quote/512290.CN.md)
- [GF CSI HK Innovative Drugs Industry ETF(QDII) (513120.CN)](https://longbridge.com/zh-CN/quote/513120.CN.md)
- [Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII) (520500.CN)](https://longbridge.com/zh-CN/quote/520500.CN.md)
- [China Merchants CSI Biotechnology Theme ETF (159849.CN)](https://longbridge.com/zh-CN/quote/159849.CN.md)
- [Penghua CSI HK Connect Health Care Composite ETF (513700.CN)](https://longbridge.com/zh-CN/quote/513700.CN.md)
- [Hwabao WP Hang Seng SCHK Innovative Drug Select ETF (520880.CN)](https://longbridge.com/zh-CN/quote/520880.CN.md)
- [Bosera Hang Seng SCHK Innovative Drug Select ETF (520690.CN)](https://longbridge.com/zh-CN/quote/520690.CN.md)
- [Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF (159506.CN)](https://longbridge.com/zh-CN/quote/159506.CN.md)
- [ChinaAMC SSE Health Care ETF Initiating Fund (510660.CN)](https://longbridge.com/zh-CN/quote/510660.CN.md)
- [Minsheng Royal CSI Biotechnology Theme ETF (516930.CN)](https://longbridge.com/zh-CN/quote/516930.CN.md)
- [China Universal CNI HK Connect Innovative Drugs Industry ETF (159570.CN)](https://longbridge.com/zh-CN/quote/159570.CN.md)
- [E Fund CSI 300 Health Care ETF (512010.CN)](https://longbridge.com/zh-CN/quote/512010.CN.md)

## 相关资讯与研究

- [3SBio Nearly Doubles Revenue and Quadruples Profit in 2025, Keeps Dividend Steady](https://longbridge.com/zh-CN/news/281054154.md)
- [ImmuneOnco Doses First Patient in Phase III Trial of CD47/CD20 Bispecific for Lymphoma](https://longbridge.com/zh-CN/news/281068292.md)
- [Annovis Bio Director Purchased Shares Worth Over $1.4M](https://longbridge.com/zh-CN/news/281662341.md)
- [Junshi Biosciences Chairman Completes RMB100 Million Shareholding Increase](https://longbridge.com/zh-CN/news/281231901.md)
- [SSY Group Wins China Approval for Upadacitinib Bulk Drug](https://longbridge.com/zh-CN/news/281103720.md)